(Q39340230)

English

Real-life treatment of acute exacerbations of chronic bronchitis with moxifloxacin or macrolides: a comparative post-marketing surveillance study in general practice

scientific article published on January 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Real-life treatment of acute exacerbations of chronic bronchitis with moxifloxacin or macrolides: a comparative post-marketing surveillance study in general practice (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Schaberg T

1

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Möller M

2

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

File T

3

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Stauch K

4

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Landen H

5

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

publication date

1 January 2006

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Clinical Drug Investigation

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

733-744

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.2165%2F00044011-200626120-00007

21 January 2018

Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study.

1 reference

https://api.crossref.org/works/10.2165%2F00044011-200626120-00007

21 January 2018

Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.2165%2F00044011-200626120-00007

21 January 2018

Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.2165%2F00044011-200626120-00007

21 January 2018

Moxifloxacin sensitivity of respiratory pathogens in the United Kingdom

1 reference

https://api.crossref.org/works/10.2165%2F00044011-200626120-00007

21 January 2018

Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis.

1 reference

https://api.crossref.org/works/10.2165%2F00044011-200626120-00007

21 January 2018

A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis

1 reference

https://api.crossref.org/works/10.2165%2F00044011-200626120-00007

21 January 2018

Efficacy and safety of short course (5-day) moxifloxacin vs 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB).

1 reference

https://api.crossref.org/works/10.2165%2F00044011-200626120-00007

21 January 2018

Speed of Recovery from Acute Exacerbations of Chronic Obstructive Pulmonary Disease after Treatment with Antimicrobials

1 reference

https://pubmed.ncbi.nlm.nih.gov/17274680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/17274680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States (1999).

1 reference

https://pubmed.ncbi.nlm.nih.gov/17274680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/17274680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Guidelines for the treatment of acute exacerbations of chronic bronchitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17274680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antimicrobial susceptibilities of Streptococcus pyogenes isolated from respiratory and skin and soft tissue infections: United States LIBRA surveillance data from 1999.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17274680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infectious etiology of acute exacerbations of chronic bronchitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17274680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17274680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17274680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quality of life in acute exacerbation of chronic bronchitis: results from a German population study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17274680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

National surveillance programme on susceptibility patterns of respiratory pathogens in South Africa: moxifloxacin compared with eight other antimicrobial agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/17274680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function

1 reference

https://pubmed.ncbi.nlm.nih.gov/17274680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States

1 reference

https://pubmed.ncbi.nlm.nih.gov/17274680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/17274680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Canadian guidelines for the management of acute exacerbations of chronic bronchitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17274680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17274680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Guidelines for the management of adult lower respiratory tract infections

1 reference

https://pubmed.ncbi.nlm.nih.gov/17274680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Airway inflammation and etiology of acute exacerbations of chronic bronchitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17274680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and tolerability of moxifloxacin in 2338 patients with acute exacerbation of chronic bronchitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17274680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17274680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidemiology of community-acquired respiratory tract infections in adults. Incidence, etiology, and impact

1 reference

https://pubmed.ncbi.nlm.nih.gov/17274680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones'.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17274680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Benchmarking the in vitro activity of moxifloxacin against recent isolates of Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae. A European multi-centre study

1 reference

https://pubmed.ncbi.nlm.nih.gov/17274680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17274680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00044011-200626120-00007

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39340230&oldid=1820760722"